Aprea Therapeutics Inc.

4.54+0.0100+0.22%Vol 1.07M1Y Perf -78.95%
Sep 24th, 2021 16:00 DELAYED
BID4.53 ASK4.60
Open4.50 Previous Close4.53
Pre-Market- After-Market-
 - -  - -%
Target Price
4.00 
Analyst Rating
Moderate Buy 2.00
Potential %
-11.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.92 
Earnings Rating
Market Cap96.19M 
Earnings Date
4th Nov 2021
Alpha-0.02 Standard Deviation0.30
Beta-0.01 

Today's Price Range

4.414.76

52W Range

3.1730.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-10.28%
1 Month
14.07%
3 Months
-9.56%
6 Months
-12.86%
1 Year
-78.95%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APRE4.540.01000.22
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.47-0.48-2.13
Q01 2021-0.52-0.4611.54
Q04 2020-0.63-0.73-15.87
Q03 2020-0.77-0.5824.68
Q02 2020-0.60-0.78-30.00
Q01 2020-0.57-0.4521.05
Q04 2019-0.39-0.64-64.10
Q03 2019-5.88-5.2910.03
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.44
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.07M
Shares Outstanding21.19M
Shares Float18.54M
Trades Count5.35K
Dollar Volume6.19M
Avg. Volume2.11M
Avg. Weekly Volume6.72M
Avg. Monthly Volume2.11M
Avg. Quarterly Volume1.75M

Aprea Therapeutics Inc. (NASDAQ: APRE) stock closed at 4.54 per share at the end of the most recent trading day (a 0.22% change compared to the prior day closing price) with a volume of 1.09M shares and market capitalization of 96.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aprea Therapeutics Inc. CEO is Christian S. Schade.

The one-year performance of Aprea Therapeutics Inc. stock is -78.95%, while year-to-date (YTD) performance is -7.72%. APRE stock has a five-year performance of %. Its 52-week range is between 3.17 and 30.99, which gives APRE stock a 52-week price range ratio of 4.92%

Aprea Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 1.76, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.11%, a ROC of -58.91% and a ROE of -59.14%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aprea Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. Aprea Therapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Aprea Therapeutics Inc. is Moderate Buy (2), with a target price of $4, which is -11.89% compared to the current price. The earnings rating for Aprea Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aprea Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aprea Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.27, ATR14 : 0.35, CCI20 : -15.54, Chaikin Money Flow : -0.28, MACD : 0.09, Money Flow Index : 68.67, ROC : 2.25, RSI : 50.81, STOCH (14,3) : 17.32, STOCH RSI : 0.06, UO : 48.82, Williams %R : -82.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aprea Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (25.00 %)
0 (0.00 %)
Moderate Buy
1 (33.33 %)
1 (25.00 %)
1 (33.33 %)
Hold
1 (33.33 %)
2 (50.00 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.25
Hold
2.67

Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

CEO: Christian S. Schade

Telephone: +1 617 463-9385

Address: 535 Boylston Street, Boston 02116, MA, US

Number of employees: 13

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

Bearish Bullish

51%49%

TipRanks News for APRE

Mon, 09 Aug 2021 10:18 GMT Aprea Therapeutics (APRE) Receives a Hold from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 06 Aug 2021 20:45 GMT Aprea Therapeutics (APRE) Gets a Buy Rating from Berenberg Bank

- TipRanks. All rights reserved.

News

Stocktwits